



SAFETY DATA SHEET

Revision date: 25-Mar-2014

Version: 2.0

Page 1 of 11

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Linezolid Tablets

Trade Name: ZYVOX, ZYVOXID

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Specific target organ systemic toxicity (repeated exposure): Category 2

EU Classification:

EU Indication of danger: Harmful

EU Risk Phrases:

R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Label Elements

Signal Word: Warning

Hazard Statements: H373 - May cause damage to organs through prolonged or repeated exposure

Precautionary Statements: P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P314 - Get medical attention/advice if you feel unwell
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Linezolid Tablets
Revision date: 25-Mar-2014

Page 2 of 11
Version: 2.0



Other Hazards
Australian Hazard Classification (NOHSC):

No data available
Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Magnesium stearate	557-04-0	209-150-3	Not Listed	Not Listed	*
Corn Starch	9005-25-8	232-679-6	Not Listed	Not Listed	*
Titanium dioxide	13463-67-7	236-675-5	Not Listed	Not Listed	*
Linezolid	165800-03-3	Not Listed	Xn;R48/22	STOT RE 2 (H373)	70
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Carnauba wax	8015-86-9	232-399-4	Not Listed	Not Listed	*
Polyethylene glycol	25322-68-3	Not Listed	Not Listed	Not Listed	*
Sodium starch glycolate	9063-38-1	Not Listed	Not Listed	Not Listed	*
Hydroxypropyl cellulose	9004-64-2	Not Listed	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

SAFETY DATA SHEET

Material Name: Linezolid Tablets
Revision date: 25-Mar-2014

Page 3 of 11
Version: 2.0

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

SAFETY DATA SHEET

Material Name: Linezolid Tablets
Revision date: 25-Mar-2014

Page 4 of 11
Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Magnesium stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Corn Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL -TWAs	3 mg/m ³

Polyethylene glycol

Austria OEL - MAKs	1000 mg/m ³
Germany - TRGS 900 - TWAs	1000 mg/m ³
Germany (DFG) - MAK	1000 mg/m ³ average molecular weight 200-600
Slovakia OEL - TWA	1000 mg/m ³
Slovenia OEL - TWA	1000 mg/m ³
Switzerland OEL -TWAs	1000 ppm

Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
ACGIH OELs - Notice of Intended Changes	Listed
Australia TWA	10 mg/m ³
Austria OEL - MAKs	5 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Denmark OEL - TWA	6 mg/m ³
Estonia OEL - TWA	5 mg/m ³
France OEL - TWA	10 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
Latvia OEL - TWA	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Poland OEL - TWA	10.0 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³

SAFETY DATA SHEET

Material Name: Linezolid Tablets
Revision date: 25-Mar-2014

Page 5 of 11
Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Russia OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Sweden OEL - TWAs	5 mg/m ³
Switzerland OEL -TWAs	3 mg/m ³
Vietnam OEL - TWAs	6 mg/m ³
	5 mg/m ³

Linezolid

Pfizer OEL TWA-8 Hr:	750µg/m ³
----------------------	----------------------

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
Latvia OEL - TWA	2 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³
Russia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL -TWAs	3 mg/m ³
Vietnam OEL - TWAs	10 mg/m ³
	5 mg/m ³

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:

Tablet

Color:

White

Odor:

No data available.

Odor Threshold:

No data available.

Molecular Formula:

Mixture

Molecular Weight:

Mixture

Solvent Solubility:

No data available

Water Solubility:

No data available

pH:

No data available.

Melting/Freezing Point (°C):

No data available

SAFETY DATA SHEET

Material Name: Linezolid Tablets
Revision date: 25-Mar-2014

Page 6 of 11
Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Boiling Point (°C): No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Linezolid

Measured 6-8 Log D 0.55

Microcrystalline cellulose

No data available

Magnesium stearate

No data available

Corn Starch

No data available

Carnauba wax

No data available

Polyethylene glycol

No data available

Sodium starch glycolate

No data available

Hydroxypropyl cellulose

No data available

Titanium dioxide

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The following information is available for the individual ingredients.

Short Term: May cause minimal eye irritation (based on animal data). May cause negligible skin irritation (based on animal data). Not acutely toxic (based on animal data). May cause stomach irritation, diarrhea, nausea, or vomiting.

SAFETY DATA SHEET

Material Name: Linezolid Tablets
Revision date: 25-Mar-2014

Page 7 of 11
Version: 2.0

11. TOXICOLOGICAL INFORMATION

Long Term: Animal studies have shown a potential to cause adverse effects on the fetus. Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system.

Known Clinical Effects: The most common adverse effects reported with clinical use were diarrhea, nausea, rash, and vomiting. Effects on blood and blood-forming organs have also occurred.

Acute Toxicity: (Species, Route, End Point, Dose)

Linezolid

Rat (F) Oral Minimum Lethal Dose 5000 mg/kg
Rat (M) Oral Minimum Lethal Dose > 5000mg/kg
Dog Oral Minimum Lethal Dose > 2000mg/kg

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg
Rat Subcutaneous LD50 50 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Linezolid

Eye Irritation Rabbit Minimal
Skin Irritation Rabbit Minimal
Antigenicity- Passive cutaneous anaphylaxis Mouse Negative
Antigenicity- Active anaphylaxis Guinea Pig Negative

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Non-irritating

Polyethylene glycol

Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Linezolid

1 Month(s)	Rat	Oral	20 mg/kg/day	NOAEL	Blood forming organs, Blood
3 Month(s)	Rat	Oral	10 mg/kg/day	NOAEL	Blood forming organs, Blood
1 Month(s)	Dog	Oral	20 mg/kg/day	NOAEL	Blood forming organs, Blood, Gastrointestinal system
3 Month(s)	Dog	Oral	20 mg/kg/day	NOAEL	Blood forming organs, Blood, Gastrointestinal system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

SAFETY DATA SHEET

Material Name: Linezolid Tablets
Revision date: 25-Mar-2014

Page 8 of 11
Version: 2.0

11. TOXICOLOGICAL INFORMATION

Linezolid

Reproductive & Fertility	Rat	Oral	50 mg/kg/day	NOAEL	Fertility
Embryo / Fetal Development	Rat	Oral	2.5 mg/kg/day	NOAEL	Fetotoxicity, Not Teratogenic
Embryo / Fetal Development	Rat	Oral	15 mg/kg/day	NOAEL	Maternal Toxicity
Embryo / Fetal Development	Mouse	Oral	150 mg/kg/day	NOAEL	Fetotoxicity, Maternal Toxicity, Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Linezolid

<i>In Vitro</i> Unscheduled DNA Synthesis	Negative
Bacterial Mutagenicity (Ames) <i>Salmonella</i>	Negative
<i>In Vitro</i> Chromosome Aberration Human Lymphocytes	Negative
<i>In Vivo</i> Micronucleus Mouse	Negative

Carcinogen Status: See below

Titanium dioxide

IARC: Group 2B (Possibly Carcinogenic to Humans)
OSHA: Listed

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Linezolid

<i>Daphnia magna</i> (Water Flea)	OECD	EC50	48 Hours	> 100 mg/L
<i>Oncorhynchus mykiss</i> (Rainbow Trout)	OECD	LC50	96 Hours	> 1.4 mg/L
<i>Anabaena flos-aquae</i> (Cyanobacteria)	Algae	OECD	ErC50	72 Hours 1.5 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Linezolid

Activated sludge OECD EC50 > 1000 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Linezolid

Measured 6-8 Log D 0.55

Mobility in Soil: No data available

SAFETY DATA SHEET

Material Name: Linezolid Tablets
Revision date: 25-Mar-2014

Page 9 of 11
Version: 2.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision B



Magnesium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

Corn Starch

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

Carnauba wax

CERCLA/SARA 313 Emission reporting	Not Listed
------------------------------------	------------

SAFETY DATA SHEET

Material Name: Linezolid Tablets
Revision date: 25-Mar-2014

Page 10 of 11
Version: 2.0

15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-399-4
Polyethylene glycol	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 3
EU EINECS/ELINCS List	Not Listed
Sodium starch glycolate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Hydroxypropyl cellulose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Titanium dioxide	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 9/2/11 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5
Linezolid	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed
Microcrystalline cellulose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 12/18/09
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex XVII - Restrictions on Certain Dangerous Substances:	Use restricted. See item 9[f]. powder
EU EINECS/ELINCS List	232-674-9

SAFETY DATA SHEET

Material Name: Linezolid Tablets
Revision date: 25-Mar-2014

Page 11 of 11
Version: 2.0

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure

Xn - Harmful

R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 3 - Composition / Information on Ingredients. Updated Section 2 - Hazard Identification. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date: 25-Mar-2014

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet